UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation

The New England journal of medicine, 2010-11, Vol.363 (21), p.1991-2003

2010

Volltextzugriff (PDF)

Diagnostic Testing in Cystic Fibrosis

Clinics in chest medicine, 2016-03, Vol.37 (1), p.31-46

2016

Volltextzugriff (PDF)

Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study

Journal of cystic fibrosis, 2015-01, Vol.14 (1), p.111-119

2015

Volltextzugriff (PDF)

EPS5.8 Dynamic prediction modeling to identify rapid lung function decline in cystic fibrosis

Journal of cystic fibrosis, 2017-06, Vol.16, p.S49-S49

2017

Volltextzugriff (PDF)

WS18.3 High β-agonist exposure impairs adenylyl cyclase-dependent activation of CFTR in human airway epithelia

Journal of cystic fibrosis, 2017-06, Vol.16, p.S30-S31

2017

Volltextzugriff (PDF)

WS03.5 Invasive sampling that bypasses the oropharynx provides insights into the lung microbiota of children with CF and mild lung disease

Journal of cystic fibrosis, 2017-06, Vol.16, p.S5-S6

2017

Volltextzugriff (PDF)

Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line

Nature medicine, 1997-11, Vol.3 (11), p.1280-1284

1997

Volltextzugriff (PDF)

ΔF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers

Pulmonary pharmacology & therapeutics, 2010-08, Vol.23 (4), p.268-278

2010

Volltextzugriff (PDF)

WS3.3 MRI-based pulmonary blood flow and lung function in CF patients – flow changes with pulmonary decline

Journal of cystic fibrosis, 2014-06, Vol.13, p.S6-S6

2014

Volltextzugriff (PDF)

WS13.1 QR-010, an investigational RNA therapeutic, improves CFTR activity in cystic fibrosis subjects homozygous for the F508del mutation

Journal of cystic fibrosis, 2017-06, Vol.16, p.S23-S23

2017

Volltextzugriff (PDF)

110 Aztreonam for inhalation solution (AZLI) for eradication of new onset Pseudomonas aeruginosa ( PA ) infection in children with cystic fibrosis (CF): Evaluation of treatment failures

Journal of cystic fibrosis, 2015-06, Vol.14, p.S85-S85

2015

Volltextzugriff (PDF)

WS02.2 Aztreonam for inhalation solution (AZLI) for eradication of new onset Pseudomonas aeruginosa ( PA ) infection in children with cystic fibrosis (CF): Results of facemask vs. nebulizer mouthpiece use

Journal of cystic fibrosis, 2015-06, Vol.14, p.S3-S3

2015

Volltextzugriff (PDF)

EPS1.3 Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: study design and rationale for the Rio-CF study

Journal of cystic fibrosis, 2017-06, Vol.16, p.S36-S36

2017

Volltextzugriff (PDF)

112 Analysis of long-term use of liposomal amikacin for inhalation (LAI) in patients with cystic fibrosis (CF) who have chronic infection from Pseudomonas aeruginosa

Journal of cystic fibrosis, 2015-06, Vol.14, p.S85-S85

2015

Volltextzugriff (PDF)

Clinical evaluation of VX-809, a novel investigational oral F508del-CFTR corrector, in subjects with cystic fibrosis homozygous for the F508del–CFTR mutation

Journal of cystic fibrosis, 2010, Vol.9, p.S20-S20

2010

Volltextzugriff (PDF)

WS7.3 Once-daily liposomal amikacin for inhalation is noninferior to twice-daily tobramycin inhalation solution in improving pulmonary function in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa

Journal of cystic fibrosis, 2014-06, Vol.13, p.S15-S15

2014

Volltextzugriff (PDF)

Magnetic anisotropy in geometrically frustrated kagome staircase lattices

Journal of magnetism and magnetic materials, 2009-04, Vol.321 (7), p.793-795

2009

Volltextzugriff (PDF)

Take it to the Bank

Journal of cystic fibrosis, 2017-09, Vol.16 (5), p.532-533

2017

Volltextzugriff (PDF)

Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study

Journal of cystic fibrosis, 2022-01, Vol.21 (1), p.143-145

2022

Volltextzugriff (PDF)

P090 Treatment use among SIMPLIFY trial participants through 24 weeks of follow-up

Journal of cystic fibrosis, 2023-06, Vol.22, p.S91-S91

2023

Volltextzugriff (PDF)

Dissociation of systemic and mucosal autoimmunity in cystic fibrosis

Journal of cystic fibrosis, 2020-03, Vol.19 (2), p.196-202

2020

Volltextzugriff (PDF)

Parallel effects of VX-770 on transepithelial potential difference in vitro and in vivo

Journal of cystic fibrosis, 2010, Vol.9, p.S20-S20

2010

Volltextzugriff (PDF)

WS15.02 A joint model for lung function and nutritional status decline with recurrent pulmonary exacerbations, death, and lung transplantation using cystic fibrosis patient Registry data

Journal of cystic fibrosis, 2022-06, Vol.21, p.S29

2022

Volltextzugriff (PDF)

WS07.05 Investigating the relationship between lung function decline and time to death or lung transplantation, accounting for geographical variability

Journal of cystic fibrosis, 2022-06, Vol.21, p.S14-S15

2022

Volltextzugriff (PDF)

WS13.06 Regional bronchoscopy sampling indicates that Pseudomonas aeruginosa infections persist throughout the lung after elexacaftor/tezacaftor/ivacaftor (ETI) due to intra-lung bacterial migration

Journal of cystic fibrosis, 2023-06, Vol.22, p.S27-S27

2023

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Englisch
(72)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation

Diagnostic Testing in Cystic Fibrosis

Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study

EPS5.8 Dynamic prediction modeling to identify rapid lung function decline in cystic fibrosis

WS18.3 High β-agonist exposure impairs adenylyl cyclase-dependent activation of CFTR in human airway epithelia

WS03.5 Invasive sampling that bypasses the oropharynx provides insights into the lung microbiota of children with CF and mild lung disease

Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line

ΔF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers

WS3.3 MRI-based pulmonary blood flow and lung function in CF patients – flow changes with pulmonary decline

WS13.1 QR-010, an investigational RNA therapeutic, improves CFTR activity in cystic fibrosis subjects homozygous for the F508del mutation

110 Aztreonam for inhalation solution (AZLI) for eradication of new onset Pseudomonas aeruginosa ( PA ) infection in children with cystic fibrosis (CF): Evaluation of treatment failures

WS02.2 Aztreonam for inhalation solution (AZLI) for eradication of new onset Pseudomonas aeruginosa ( PA ) infection in children with cystic fibrosis (CF): Results of facemask vs. nebulizer mouthpiece use

EPS1.3 Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: study design and rationale for the Rio-CF study

112 Analysis of long-term use of liposomal amikacin for inhalation (LAI) in patients with cystic fibrosis (CF) who have chronic infection from Pseudomonas aeruginosa

Clinical evaluation of VX-809, a novel investigational oral F508del-CFTR corrector, in subjects with cystic fibrosis homozygous for the F508del–CFTR mutation

WS7.3 Once-daily liposomal amikacin for inhalation is noninferior to twice-daily tobramycin inhalation solution in improving pulmonary function in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa

Magnetic anisotropy in geometrically frustrated kagome staircase lattices

Take it to the Bank

Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study

P090 Treatment use among SIMPLIFY trial participants through 24 weeks of follow-up

Dissociation of systemic and mucosal autoimmunity in cystic fibrosis

Parallel effects of VX-770 on transepithelial potential difference in vitro and in vivo

WS15.02 A joint model for lung function and nutritional status decline with recurrent pulmonary exacerbations, death, and lung transplantation using cystic fibrosis patient Registry data

WS07.05 Investigating the relationship between lung function decline and time to death or lung transplantation, accounting for geographical variability

WS13.06 Regional bronchoscopy sampling indicates that Pseudomonas aeruginosa infections persist throughout the lung after elexacaftor/tezacaftor/ivacaftor (ETI) due to intra-lung bacterial migration

Suchergebnisse filtern